Recombinant allergens: What does the future hold?

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial Kaarina.

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality Allan Linneberg,

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Allergen immunotherapy: A practice parameter third update

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Fatty acids, inflammation, and asthma

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality Allan Linneberg,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy Margarete Focke-Tejkl, PhD, Milena.

Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life? Gennaro Liccardi, MD, Antonello Salzillo, MD, Maria.

Delineating the specificity of an IgE-encoding transcriptome

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 Verena Niederberger, MD, Angela Neubauer, PhD,

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Desensitization to Chemotherapeutic Agents

Safety of allergen immunotherapy: A 10-year prospective study

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012 Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Analysis of serum IgE reactivity profiles with microarrayed allergens indicates absence of de novo IgE sensitizations in adults Christian Lupinek, MD,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel.

Etiology of asthma exacerbations

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Phillip Lieberman, MD, David Golden, MD

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Children's compliance with allergen immunotherapy according to administration routes Giovanni Battista Pajno, MD, Daniela Vita, MD, Lucia Caminiti, MD,

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

What is an “eosinophilic phenotype” of asthma?

Allergenic significance of cephalosporin side chains

Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen– allergic patients Verena Niederberger, MD, Katharina Marth, MD,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

The Editors' Choice Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS Katarzyna Niespodziana, MSc, Margarete Focke-Tejkl, PhD, Birgit.

Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: A preclinical study Ousama Rachid, BPharm, MSc, Mutasem M.

Reply Journal of Allergy and Clinical Immunology

Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro.

A general strategy for the generation of hypoallergenic molecules for the immunotherapy of fish allergy Ines Swoboda, PhD, Nadja Balic, Christoph Klug,

Measles and immunomodulation

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Environmental factors and eosinophilic esophagitis

The GILL study: Glycerin-induced local reactions in immunotherapy

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Advances in pediatric asthma in 2007

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood Adnan Custovic, MD, PhD, Lars Soderstrom,

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison Janine Dretzke, MSc, Angela Meadows,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Brian F. Leas, MS, MA, Kristen E. D'Anci, PhD, Andrea J

Presentation transcript:

Recombinant allergens: What does the future hold? Rudolf Valenta, MD, Katarzyna Niespodziana, MSc, Margit Focke-Tejkl, PhD, Katharina Marth, MD, Hans Huber, PhD, Angela Neubauer, PhD, Verena Niederberger, MD Journal of Allergy and Clinical Immunology Volume 127, Issue 4, Pages 860-864 (April 2011) DOI: 10.1016/j.jaci.2011.02.016 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 From allergen-encoding DNA to recombinant allergen–based vaccines. Allergen portions constituting conformational IgE epitopes on wild-type allergens are indicated in red and green, with the remaining allergen sequence in black. In fusion proteins large parts of the allergen are replaced by a foreign carrier protein (blue). Journal of Allergy and Clinical Immunology 2011 127, 860-864DOI: (10.1016/j.jaci.2011.02.016) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Currently ongoing development lines for recombinant allergen–based vaccines. NCT numbers identify the trials that are registered in the National Institutes of Health Clinical trial database (http://clinicaltrials.gov). DBPC, Double-blind, placebo-controlled; OC, open controlled; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy. Journal of Allergy and Clinical Immunology 2011 127, 860-864DOI: (10.1016/j.jaci.2011.02.016) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions